(Q77495165)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797695%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

title

Weekly docetaxel and concomitant boost radiotherapy for non-small cell lung cancer. A phase I/II dose escalation trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797695%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

main subject

phase I clinical trial

1 reference

1 reference

M I Koukourakis

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797695%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

C Kourousis

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797695%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

M Kamilaki

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797695%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

S Koukouraki

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797695%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

A Giatromanolaki

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797695%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

S Kakolyris

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797695%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

A Kotsakis

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797695%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

N Androulakis

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797695%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

N Bahlitzanakis

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797695%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

V Georgoulias

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797695%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

publication date

1 May 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797695%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Cancer

6 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797695%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

volume

34

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797695%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797695%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

page(s)

838-844

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797695%20AND%20SRC:MED&resulttype=core&format=json

Studies With RP 56976 (Taxotere): A Semisynthetic Analogue of Taxol

6 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910101-0

7 January 2021

Relationships between the structure of taxol analogs and their antimitotic activity

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910101-0

7 January 2021

Randomised multicentre trials of CHART vs conventional radiotherapy in head and neck and non-small-cell lung cancer: an interim report. CHART Steering Committee

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910101-0

7 January 2021

The impact of overall treatment time on the results of radiotherapy for nonsmall cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910101-0

7 January 2021

The hazard of accelerated tumor clonogen repopulation during radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910101-0

7 January 2021

LQ-based model for biological radiotherapy planning

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910101-0

7 January 2021

Inoperable non-small cell lung cancer: radiation with or without chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910101-0

7 January 2021

A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910101-0

7 January 2021

Signiicant Effect of Adjuvant Chemotherapy on Survival in Locally Advanced Non-Small-Cell Lung Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910101-0

7 January 2021

Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer. A randomized, phase III trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910101-0

7 January 2021

Comparison of induction chemotherapy before radiotherapy with radiotherapy only in patients with locally advanced squamous cell carcinoma of the lung. The Swedish Lung Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910101-0

7 January 2021

Radiotherapy Alone for Non-Small Cell Lung Carcinoma Five-year disease-free survival and patterns of failure

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910101-0

7 January 2021

Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910101-0

7 January 2021

Severe lymphocytopenia and interstitial pneumonia in patients treated with paclitaxel and simultaneous radiotherapy for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910101-0

7 January 2021

Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910101-0

7 January 2021

Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG)

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910101-0

7 January 2021

Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910101-0

7 January 2021

Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910101-0

7 January 2021

p53 mutations do not predict response to paclitaxel/radiation for nonsmall cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910101-0

7 January 2021

Endpoints for multimodal clinical trials in stage III non-small cell lung cancer (NSCLC): a consensus report

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910101-0

7 January 2021

10.1016/S0959-8049(97)10101-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9797695%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

1 reference